Elysium Health was founded in 2014 by
Leonard Guarente, Dan Alminana, and Eric Marcotulli. In 2015, Elysium introduced its first product, Basis, which contains
nicotinamide riboside and
pterostilbene. In December 2016, Elysium received an investment of $20 million in
Series B funding. In 2019, Elysium introduced a test called Index that uses
epigenetic analysis on saliva samples to estimate biological age. In June 2020, Elysium launched a supplement called
Matter, which purports to maintain brain health and slow
brain aging/
atrophy. In October 2021, Elysium launched a supplement called Format, which is associated with anti-aging and
immune system support. In 2023, Elysium launched a daily supplement called
Mosaic, which claims to prevent
skin aging and protect
collagen. In October 2024, Elysium introduced a daily supplement called
Vision, to maintain macular health and promote eye longevity.
Litigation Elysium originally bought the ingredients in Basis from
ChromaDex, which as of December 2016, sold the two ingredients to other supplement companies that also marketed products containing them. The two companies had an agreement under which Elysium Health did not have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the VP of business development from ChromaDex and reportedly stopped paying ChromaDex, ChromaDex sued Elysium and the information became public. In September 2018,
Dartmouth College and ChromaDex sued Elysium for infringing on patents for nicotinamide riboside. In August 2020,
W.R. Grace and Company also sued Elysium for infringing on their patents for crystalline nicotinamide riboside. In September 2021, the claims by Dartmouth and ChromaDex were dismissed by a U.S. district judge, essentially invalidating their patents. In February 2023, the
United States Court of Appeals for the Federal Circuit affirmed the district court’s judgment that these patent infringement claims are invalid under 35 U.S.C. § 101. ==References==